Daiichi-Sankyo is a global pharmaceutical company originating from Japan and providing innovative products and services in more than 20 countries around the world. The Company primarily focuses on innovative and generic pharmaceuticals, vaccines, and over-the-counter medicines with special interest in oncology and cardiovascular and metabolic diseases.
RSA was appointed to find an Executive Director, Head of Biostatistics and Data Management Europe for Daiichi-Sankyo in preparation for the retirement of the previous incumbent. The individual would be responsible for all aspects of biostatistics support in all therapeutic areas of the Company. Additionally, the appointee would need to support the development of value dossiers to maximise market access success. Candidates needed extensive experience of people management and of the oncology sector as well as an ability to build and develop teams. They also needed to be skilled at working with CROs and collaborating with HEOR and Market Access colleagues.
How our approach made a difference:
We ran a global search, identifying pharmaceutical companies and individuals with biostatistics experience. The due diligence of RSA’s consultants yielded 123 potential candidates and this list was ultimately reduced to a final shortlist of four. The appointed individual has substantial experience working in varied environments and in diverse teams. He had previously worked in pharma, biotech and medical devices, leading several departments in biostatistics, data management and data analytics across multiple therapeutic areas. As a result, he was able to motivate the existing teams and introduce a fresh strategy at all levels.
The whole process was completed during the pandemic and the excellent outcome demonstrates The RSA Group’s ability to engage the best candidates in their fields, despite restrictions on international travel and global economic uncertainty.